Scholarly Index
Martha Q. Lacy
Mayo Clinic; 48,724 total citations; 1,044 total publications; best world rank #31
Mayo Clinic
48,724Total citations
1,044Total publications
110H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Multiple Myeloma Research and Treatments | Lifetime | 34 | US 20 | 99.77 |
| Peptidase Inhibition and Analysis | Lifetime | 70 | US 35 | 99.64 |
| Protein Degradation and Inhibitors | Lifetime | 35 | US 19 | 99.62 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 31 | US 19 | 99.32 |
| Cancer Treatment and Pharmacology | Lifetime | 135 | US 74 | 99.57 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 131 | US 68 | 98.84 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 881 | US 377 | 96.42 |
| Hematological disorders and diagnostics | Lifetime | 776 | US 342 | 91.45 |
| Chemokine receptors and signaling | Lifetime | 678 | US 263 | 92.09 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 970 | US 413 | 87.91 |
| Protein Degradation and Inhibitors | 2021-2025 | 854 | US 358 | 85.73 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 580 | US 190 | 82.90 |
| Hematological disorders and diagnostics | 2021-2025 | 870 | US 208 | 50.66 |